56 related articles for article (PubMed ID: 37316446)
1. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
2. Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion.
Li T; Tian P; Huang Q; Zeng H; Wei Q; Li Y
Clin Respir J; 2023 Nov; 17(11):1158-1168. PubMed ID: 37723659
[TBL] [Abstract][Full Text] [Related]
3. Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy.
Zhen S; Wang W; Qin G; Lu T; Yang L; Zhang Y
Front Immunol; 2024; 15():1316778. PubMed ID: 38482008
[TBL] [Abstract][Full Text] [Related]
4. Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Wang J; Zhang B; Peng L; Liu X; Sun J; Su C; Wang H; Zhao Z; Si L; Duan J; Zhang H; Li M; Zhu B; Zhang L; Li J; Guo J; Luo R; Qiu W; Ye D; Chu Q; Cui J; Dong X; Fan Y; Gao Q; Guo Y; He Z; Li W; Lin G; Liu L; Liu Y; Qin H; Ren S; Ren X; Wang Y; Xue J; Yang Y; Yang Z; Yue L; Zhan X; Zhang J; Ma J; Qin S; Wang B
Ther Adv Med Oncol; 2023; 15():17588359231187205. PubMed ID: 37484525
[TBL] [Abstract][Full Text] [Related]
5. RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies.
Pollack R; Stokar J; Lishinsky N; Gurt I; Kaisar-Iluz N; Shaul ME; Fridlender ZG; Dresner-Pollak R
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445704
[TBL] [Abstract][Full Text] [Related]
6. TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W; Chen J; Ji T; Cong X
Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
[TBL] [Abstract][Full Text] [Related]
7. Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice.
Collier JL; Pauken KE; Lee CAA; Patterson DG; Markson SC; Conway TS; Fung ME; France JA; Mucciarone KN; Lian CG; Murphy GF; Sharpe AH
J Exp Med; 2023 Oct; 220(10):. PubMed ID: 37432393
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
9. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Fa'ak F; Buni M; Falohun A; Lu H; Song J; Johnson DH; Zobniw CM; Trinh VA; Awiwi MO; Tahon NH; Elsayes KM; Ludford K; Montazari EJ; Chernis J; Dimitrova M; Sandigursky S; Sparks JA; Abu-Shawer O; Rahma O; Thanarajasingam U; Zeman AM; Talukder R; Singh N; Chung SH; Grivas P; Daher M; Abudayyeh A; Osman I; Weber J; Tayar JH; Suarez-Almazor ME; Abdel-Wahab N; Diab A
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37328287
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and tumor-infiltrating CD8
Shi M; Song Y; Zhang Y; Li L; Yu J; Hou A; Han S
Front Endocrinol (Lausanne); 2023; 14():1151714. PubMed ID: 37424874
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.
McCormick BJ; Zieman D; West-Santos C; Phillips MB
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37339826
[TBL] [Abstract][Full Text] [Related]
12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
13. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
14. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
16. [Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients
with Advanced Non-small Cell Lung Cancer after Immunotherapy].
Wang Y; Wang X; Cheng L; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):369-376. PubMed ID: 37316446
[TBL] [Abstract][Full Text] [Related]
17. Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors.
Zhong X; Ying J; Liao H; Shen L; Pan Y
Future Oncol; 2022 Jun; 18(18):2289-2300. PubMed ID: 35440175
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
